期刊文献+

阿维A胶囊联合复方甘草酸治疗寻常型银屑病疗效观察, 被引量:3

Avi A capsule joint compound glycyrrhizin treatment of psoriasis vulgaris Clinical Observation
原文传递
导出
摘要 摘要:目的:探讨阿维A胶囊联合复方甘草酸治疗寻常型银屑病临床疗效。方法:45例患者随机分为两组。治疗组口服阿维A胶囊10mg,每日3次,复方甘草酸苷片50mg,每日3次,对照组单服阿维A胶囊lOmg,疗程8周。结果:疗程结束时观察治疗组与对照有效率分别为92.11%和73.33%。治疗组与对照组比较差异有显著性(P〈o.05)。结论:阿维A联合复方甘草酸苷治疗寻常型银屑病患者疗效确切,安全性高。 Abstract:Objective:To explore Avignon A capsule of the joint compound glyeyrrhizin treatment of psoriasis vulgaris clinical efficacy. Methods: 45 patients were randomly divided into two groups. The treatment group was treated with acitretin capsules 10mg,3 times a day,compound glycyrrhizin tablets 50mg,3 times a day,control group,single--serving acitretin capsules 10mg daily for 8 weeks. Result:The end of treatment,observation of the treatment group and control efficiency of 92.11% and 73.33% respectively, Treatment group and control group the difference was significant (P〈 0.05). Conelusion;The efficacy of avermectin A joint compound glycyrrhizin treatment in patients with psoriasis vuIgaris,Very safe.
出处 《按摩与康复医学》 2012年第24期72-72,共1页 Chinese Manipulation and Rehabilitation Medicine
关键词 阿维A胶囊 复方甘草酸苷 银屑病 Avi A capsules Compound Glycyrrhizin Psoriasis
  • 相关文献

参考文献5

二级参考文献33

  • 1杨同聚,田鹤.复方甘草甜素在非肝病治疗中的临床应用[J].中国医院用药评价与分析,2004,4(3):188-189. 被引量:8
  • 2[1]Disepio D,Malhotra M,Chandraratna RA,et al.Retinoic acid receptor-nuclear factorinterleukin 6 antagonism.A novel mechanism of retinoid-dependent inhibition of a keratinocyte hyperproliferative differentiation marker[J].J Bioel Chem,1997,272:2555
  • 3[2]Duvic M,Nagpal S,Asano AT,ct al.Molecular mechanisms of tazarotene action in psoriasis[J].J Am Acad Dermatol,1997,37:s18~s24
  • 4[3]Kashihara-Sawami M,Norris AD.The state of differentiation of cultured human keratinocytes determines the level of intercellular adhesion molecule1(ICAM-1) Expression induced by γ interferon[J].J Invest Dermatol,1992,98:741~747
  • 5[4]Nagpal S,Patel S,Asano AT,et al.Tazarotene-incluced genel(TIG1),a novel retinoic acid receptor-responsive gene in skin[J].J Invest Dermatol,1996,106:269~274
  • 6[5]Nagpal S,Patel S,Jacobe H,et al.Tazarotene-induced gene2(TIG2),a novel retinoid-responsive gene in skin[J].J Invest Dermatol,1997,109:91~95
  • 7[6]Disepio D,Ghosn C,Eckert RL,et al.Identification and characterization of a retinoidinduced class Ⅱ tumor suppressor/growth regulatory gene[J].Proc Natl Acad Sci USA,1998,95:14811~14815
  • 8[7]Virtanen M,Torma H,Vahlquist A.Keratin 4 upregulation by retinoic acid in vivo:A sensitive marker for retinoid bioactivity in human epidermis[J].J Invest Dermatol,2000,114:487~493
  • 9[8]Tang-Liu DD,Matsumoto RM,Usansky JI.Clinical Pharmacokinetics and drug metabolism of tazarotene:a novel topical treatment for acne and psoriasis[J].Clin Pharmacokinet,1999,37:273~287
  • 10[9]Marks R.Pharmacokinetics and safety review of tazarotene[J].J Am Acad Dermatol,1998,39:S134~138

共引文献160

同被引文献28

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部